

# Rheumatoid Arthritis - Pipeline Review, H2 2020

<https://marketpublishers.com/r/R2DFCFFD979EN.html>

Date: July 2020

Pages: 1191

Price: US\$ 2,500.00 (Single User License)

ID: R2DFCFFD979EN

## Abstracts

Rheumatoid Arthritis - Pipeline Review, H2 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rheumatoid Arthritis - Pipeline Review, H2 2020, provides an overview of the Rheumatoid Arthritis (Immunology) pipeline landscape.

Rheumatoid arthritis (RA) is an autoimmune chronic disorder that eventually leads to destruction of bones causing deformities. Signs and symptoms of rheumatoid arthritis include tender, warm, swollen joints, fatigue, and fever and weight loss. Rheumatoid arthritis may be a result of genetic and certain specific environmental factors. Women are much more susceptible to develop RA. Treatment includes non-steroidal anti-inflammatory drugs, corticosteroid medications and immunosuppressants.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rheumatoid Arthritis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Rheumatoid Arthritis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rheumatoid Arthritis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Rheumatoid Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed,

Preclinical, Discovery and Unknown stages are 12, 2, 29, 43, 73, 10, 214, 59 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 5, 26 and 3 molecules, respectively.

Rheumatoid Arthritis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Rheumatoid Arthritis (Immunology).

The pipeline guide reviews pipeline therapeutics for Rheumatoid Arthritis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Rheumatoid Arthritis (Immunology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Rheumatoid Arthritis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Rheumatoid Arthritis (Immunology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Rheumatoid Arthritis (Immunology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Rheumatoid Arthritis (Immunology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Rheumatoid Arthritis - Overview

Rheumatoid Arthritis - Therapeutics Development

Rheumatoid Arthritis - Therapeutics Assessment

Rheumatoid Arthritis - Companies Involved in Therapeutics Development

Rheumatoid Arthritis - Drug Profiles

Rheumatoid Arthritis - Dormant Projects

Rheumatoid Arthritis - Discontinued Products

Rheumatoid Arthritis - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Rheumatoid Arthritis, H2 2020  
Number of Products under Development by Companies, H2 2020  
Number of Products under Development by Universities/Institutes, H2 2020  
Number of Products under Development by Universities/Institutes, H2 2020 (Contd..1),  
H2 2020  
Products under Development by Companies, H2 2020  
Products under Development by Universities/Institutes, H2 2020  
Products under Development by Universities/Institutes, H2 2020 (Contd..1), H2 2020  
Number of Products by Stage and Target, H2 2020  
Number of Products by Stage and Mechanism of Action, H2 2020  
Number of Products by Stage and Route of Administration, H2 2020  
Number of Products by Stage and Molecule Type, H2 2020  
Rheumatoid Arthritis - Pipeline by 3SBio Inc, H2 2020  
Rheumatoid Arthritis - Pipeline by 4D Pharma Plc, H2 2020  
Rheumatoid Arthritis - Pipeline by AB Science SA, H2 2020  
Rheumatoid Arthritis - Pipeline by AbbVie Inc, H2 2020  
Rheumatoid Arthritis - Dormant Projects, H2 2020  
Rheumatoid Arthritis - Discontinued Products, H2 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Rheumatoid Arthritis, H2 2020  
Number of Products under Development by Companies, H2 2020  
Number of Products under Development by Universities/Institutes, H2 2020  
Number of Products by Top 10 Targets, H2 2020  
Number of Products by Stage and Top 10 Targets, H2 2020  
Number of Products by Top 10 Mechanism of Actions, H2 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020  
Number of Products by Top 10 Routes of Administration, H2 2020  
Number of Products by Stage and Top 10 Routes of Administration, H2 2020  
Number of Products by Top 10 Molecule Types, H2 2020  
Number of Products by Stage and Top 10 Molecule Types, H2 2020

### COMPANIES MENTIONED

3SBio Inc  
4D Pharma Plc  
AB Science SA  
AbbVie Inc  
AbClon Inc  
Abivax SA  
Ablynx NV  
ACEA Therapeutics Inc  
Acelerox LLC  
Aclaris Therapeutics Inc  
Adare Pharmaceuticals Inc  
Affilogic SAS  
Agency for Science, Technology and Research  
Ahead Therapeutics SL  
Aibios Co Ltd  
AimVion AS  
Akari Therapeutics Plc  
Alibion AG  
Allied-Bristol Life Sciences LLC  
Allosterix Ltd  
Alphamab Oncology

Alpine Immune Sciences Inc  
Aluda Pharmaceuticals Inc  
Alvotech ehf  
Amgen Inc  
Amrif BV  
Anew Oncology Inc  
AnToIRx Inc  
Apaxen  
Apcegen Technologies Pvt Ltd  
Apitope International NV  
Applied Molecular Transport Inc  
Aprogen Inc  
Archigen Biotech Ltd  
arGentis Pharmaceuticals LLC  
Argenx SE  
Arrien Pharmaceuticals LLC  
Arthrogen BV  
Asahi Kasei Pharma Corp  
Astellas Pharma Inc  
AstraZeneca Plc  
Atlanthera  
Atlantic Bio Sci LLC  
Auransa Inc  
Aurigene Discovery Technologies Ltd  
Axsome Therapeutics Inc  
Axxam SpA  
Bayer AG  
Baylx Inc  
Beijing Eastern Biotech Co Ltd  
Beijing Hanmi Pharmaceutical Co Ltd  
Beijing VDJBio Co Ltd  
Bilix Co Ltd  
Bio-Cancer Treatment International Ltd  
Bio-Thera Solutions Ltd  
Biocad  
Biocon Ltd  
Biogen Inc  
Bioiberica SAU  
Biois Corp

BioLingus AG  
BioLite Inc  
Biosion Inc  
Biotech Holdings  
BioXpress Therapeutics SA  
Biozeus Pharmaceutical SA  
Bristol-Myers Squibb Co  
BTB Pharma AB  
c-a-i-r Biosciences GmbH  
C4X Discovery Holdings Plc  
Cadila Healthcare Ltd  
Can-Fite BioPharma Ltd  
CannBioRex Pharmaceuticals Corp  
Carna Biosciences Inc  
CarthroniX Inc  
CEL-SCI Corp  
Cellics Therapeutics Inc  
Cellinbio Co Ltd  
CellTex Therapeutics Corp  
Celltrion Inc  
Cellworks Group Inc  
Cerecor Inc  
CHA Biotech Co Ltd  
CheckPoint Immunology Inc  
Chengdu Hyperway Pharmaceuticals  
Chipscreen Biosciences Ltd  
Chong Kun Dang Pharmaceutical Corp  
Citryll BV  
Clevexel Pharma SAS  
Clover Biopharmaceuticals  
Coherus BioSciences Inc  
Commence Bio Inc  
Compugen Ltd  
Cour Pharmaceuticals Development Co Inc  
Crossject SA  
CSL Ltd  
Curyx Bio Inc  
CV6 Therapeutics (Ni) Ltd  
Cyclacel Pharmaceuticals Inc



Cytocom Inc  
Cyxone AB  
Daewoong Pharmaceutical Co Ltd  
DeMay Biotech  
Denali Therapeutics Inc  
Dendright Pty Ltd  
Diamyd Medical AB  
DiNonA Inc  
DM Bio Ltd  
DNX Biopharmaceuticals Inc  
Domainex Ltd  
Dr. Reddy's Laboratories Ltd  
Ducentis BioTherapeutics Ltd  
Dynavax Technologies Corp  
EHL Bio Co Ltd  
Enzene Biosciences Ltd  
Enzychem Lifesciences Corp  
Ergon Pharmaceuticals LLC  
Eternity Bioscience Inc  
Eton Pharmaceuticals Inc  
Evelo Biosciences Inc  
Fresenius Kabi SwissBioSim GmbH  
Fujifilm Kyowa Kirin Biologics Co Ltd  
Future Medicine Co Ltd  
Galapagos NV  
Gene Techno Science Co Ltd  
GeneFrontier Corp  
Genentech Inc  
Generium  
GeneScience Pharmaceuticals Co Ltd  
Genesen Co Ltd  
Genfit SA  
GenFleet Therapeutics (Shanghai) Inc  
Genor BioPharma Co Ltd  
Genosco Inc  
Genova Biotech Company Ltd  
Genrix (Shanghai) Biopharmaceutical Co Ltd  
Gismo Therapeutics Inc  
GlaxoSmithKline Plc

GNT Biotech and Medicals Corp  
GNT Pharma Co Ltd  
Guangdong Zhongsheng Pharmaceutical Co Ltd  
Guangzhou BeBetter Medicine Technology Co Ltd  
Han Wha Pharma Co Ltd  
Hana Pharm Co Ltd  
Hangzhou East China Pharmaceutical Group Co Ltd  
Hanlim Pharm Co Ltd  
Hebei Fitness Biotechnology Co Ltd  
HEC Pharm Co Ltd  
Hengenix Biotech Inc  
HitGen Inc  
HK inno.N Corp  
Hope Biosciences LLC  
HSRx Group  
Huabo Biopharm Co Ltd  
Hualan Biological Engineering Inc  
Humabs BioMed SA  
HuniLife Biotechnology Inc  
Hutchison MediPharma Ltd  
I-Mab Biopharma Co Ltd  
iBio Inc  
Ichnos Sciences Inc  
Idogen AB  
IL-2Rx Inc  
Iltoo Pharma  
ImCyse SA  
Immune Regulation Ltd  
Immungenetics AG  
Immunwork Inc  
Immutep Ltd  
Impetis Biosciences Ltd  
InflammatoRx inc  
Innate Pharma SA  
Innovent Biologics Inc  
Innovimmune Biotherapeutics Inc  
InSight Biopharmaceuticals Ltd  
Interprotein Corp  
Istesso Ltd

Japan Tobacco Inc  
Jiangsu Carephar Pharmaceutical Co Ltd  
Jiangsu Hengrui Medicine Co Ltd  
JiangSu Qyuns Therapeutics Co Ltd  
Jinyu Bio-technology Co Ltd  
Johnson & Johnson  
Jubilant Therapeutics Inc  
Jyant Technologies Inc  
Kadmon Corp LLC  
Kang Stem Biotech Co Ltd  
KBP BioSciences Co Ltd  
Kemmx Corp  
Kezar Life Sciences Inc  
KIMS Pharmaceutical Co Ltd  
Kine Sciences  
Kiniksa Pharmaceuticals Ltd  
Korea United Pharm Inc  
Kymera Therapeutics LLC  
L2 Diagnostics LLC  
Landos Biopharma Inc  
Lead Pharma Holding BV  
Leukosight Inc  
LG Chem Ltd  
LipUm AB  
LISCure Biosciences Co Ltd  
Livzon MabPharm Inc  
Lupin Ltd  
Mabion SA  
Mabpharm Ltd  
Mabtech Ltd  
Mabwell Shanghai Bioscience Co Ltd  
Mabxience Holding SL  
Maruho Co Ltd  
MedAnnex Ltd  
MENTRIK Biotech LLC  
Merck & Co Inc  
Merck KGaA  
Mesoblast Ltd  
MetiMedi Pharmaceuticals Co Ltd

MetrioPharm AG  
Microbiotix Inc  
Millennium Pharmaceuticals Inc  
Mirae Cell Bio Co Ltd  
Moogene Medi Inc  
Mycenax Biotech Inc  
MyeloRx LLC  
Nano Intelligent Biomedical Engineering Corp  
Nanode Therapeutics Inc  
Nascient Ltd  
Navigen Inc  
NeuClone Pty Ltd  
Neuracle Science Co Ltd  
Nichi-Iko Pharmaceutical Co Ltd  
North China Pharmaceutical Group New Drug Research and Development Co Ltd  
NovaCell Technology Inc  
NovalGen Ltd  
Novartis AG  
NuBioPharma LLC  
Numab Therapeutics AG  
Octagon Therapeutics Inc  
Omeros Corp  
Oncodesign SA  
OncolImmune Inc  
Oneness Biotech Co Ltd  
Oryn Therapeutics  
OSE Immunotherapeutics  
Pahan Therapeutics  
Paras Biopharmaceuticals Finland Oy  
Peptinov SAS  
Pfizer Inc  
Pharmapraxix  
Philogen SpA  
Promethera Biosciences SA  
ProNoxis AB  
Protab Ltd  
Protalex Inc  
Qu Biologics Inc  
R Pharm

Radikal Therapeutics Inc  
Reata Pharmaceuticals Inc  
ReceptoPharm Inc  
RedHill Biopharma Ltd  
Regen BioPharma Inc  
Regenerative Arthritis & Bone Medicine Inc  
RemeGen Ltd  
Resverlogix Corp  
ReveraGen BioPharma Inc  
Rhizen Pharmaceuticals SA  
Ribomic Inc  
Richter Gedeon Nyrt  
Rigel Pharmaceuticals Inc  
Rophibio Inc  
ROS Therapeutics ApS  
Rottapharm Biotech Srl  
Saje Pharma LLC  
Sareum Holdings Plc  
SBI Biotech Co Ltd  
Sengenics International Pte Ltd  
Serene LLC  
Servatus Ltd  
Shandong Danhong Pharmaceutical Co Ltd  
Shanghai Biomabs Pharmaceuticals Co Ltd  
Shanghai Junshi Bioscience Co Ltd  
Shanghai Pharmaceutical Group Co Ltd  
Siam Bioscience Co Ltd  
Sichuan Kelun Bio-Tech Pharmaceutical Co Ltd  
Signablok Inc  
Sincere Pharmaceutical Group  
Singh Biotechnology LLC  
Sino Biopharmaceutical Ltd  
Sinocelltech Ltd  
SinoMab Bioscience Ltd  
siRNAgen Therapeutics Corp  
SomaLogic Inc  
Splash Pharmaceuticals Inc  
Suntec Medical (Taiwan) Inc  
Suzhou Connect Biopharmaceuticals Ltd

Suzhou Ribo Life Sciences Co Ltd  
Suzhou Sinovent Pharmaceuticals Co Ltd  
SynAct Pharma AB  
Synermore Biologics Co Ltd  
Taiho Pharmaceutical Co Ltd  
Takeda Pharmaceutical Co Ltd  
Tasly Pharmaceutical Group Co Ltd  
TG Therapeutics Inc  
Tiziana Life Sciences Plc  
TLL Pharmaceutical LLC  
Toleranzia AB  
Tonix Pharmaceuticals Holding Corp  
TPCera Ltd  
Translational Biosciences  
Tumorend LLC  
Turgut Ilaclari AS  
Twoxar Inc  
United Biomedical Inc  
United BioPharma Inc  
Vaccinex Inc  
Vanworld Pharmaceutical (Rugao) Company Ltd  
Vascular Biogenics Ltd  
Viela Bio Inc  
Voronoi  
Wuhan Institute of Biological Products Co Ltd  
Wuxi Fuxin Pharmaceutical Research and Development Co Ltd  
X-Rx Inc  
Xalud Therapeutics Inc  
Xbrane Biopharma AB  
Xencor Inc  
XL-protein GmbH  
Y-Biologics Inc  
Yichang Humanwell Pharmaceutical Co Ltd  
Yuhan Corp  
Yungjin Pharm Co Ltd  
Zhejiang Hisun Pharmaceutical Co Ltd  
Zumutor Biologics Inc  
ZyVersa Therapeutics Inc

## I would like to order

Product name: Rheumatoid Arthritis - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/R2DFCFFD979EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R2DFCFFD979EN.html>